MX2022008016A - Compuesto antagonista de pd-l1. - Google Patents

Compuesto antagonista de pd-l1.

Info

Publication number
MX2022008016A
MX2022008016A MX2022008016A MX2022008016A MX2022008016A MX 2022008016 A MX2022008016 A MX 2022008016A MX 2022008016 A MX2022008016 A MX 2022008016A MX 2022008016 A MX2022008016 A MX 2022008016A MX 2022008016 A MX2022008016 A MX 2022008016A
Authority
MX
Mexico
Prior art keywords
antagonist compound
compound
formula
prevent
well
Prior art date
Application number
MX2022008016A
Other languages
English (en)
Inventor
Zhiyong Yu
Pan Li
Yu Zhou
Meng Lv
Beidi Xu
Wei Pang
Qiaodong Wen
Yongqiang Shi
Zhao Sun
Original Assignee
Adlai Nortye Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adlai Nortye Biopharma Co Ltd filed Critical Adlai Nortye Biopharma Co Ltd
Publication of MX2022008016A publication Critical patent/MX2022008016A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan un compuesto de Fórmula (I) y una composición farmacéutica del mismo, así como un método para usar los compuestos de Fórmula (I) para prevenir y/o tratar trastornos relacionados con el sistema inmunitario. (ver Fórmula).
MX2022008016A 2019-12-26 2020-12-22 Compuesto antagonista de pd-l1. MX2022008016A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911368320 2019-12-26
PCT/CN2020/138157 WO2021129584A1 (zh) 2019-12-26 2020-12-22 Pd-l1拮抗剂化合物

Publications (1)

Publication Number Publication Date
MX2022008016A true MX2022008016A (es) 2022-07-27

Family

ID=76574838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008016A MX2022008016A (es) 2019-12-26 2020-12-22 Compuesto antagonista de pd-l1.

Country Status (11)

Country Link
US (1) US20230054028A1 (es)
EP (1) EP4083032A4 (es)
JP (1) JP2022552693A (es)
KR (1) KR20220121254A (es)
CN (1) CN115066423B (es)
AU (1) AU2020413555B2 (es)
CA (1) CA3160606A1 (es)
IL (1) IL294209A (es)
MX (1) MX2022008016A (es)
WO (1) WO2021129584A1 (es)
ZA (1) ZA202206266B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250335A1 (en) * 2022-06-21 2023-12-28 Chulalongkorn University 1,4-diphenyl-1 h-indazole and 1-pyridin-2-yl-4-phenyl-1 h-indazole derivatives as pd-1/pd-l1 modulators for the treatment of cancer
CN115611700B (zh) * 2022-10-11 2024-06-14 辽宁东大光明化工科技有限责任公司 一种1-溴-2,5-二氯-3-氟苯的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015034820A1 (en) * 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US9850225B2 (en) * 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018009505A1 (en) * 2016-07-08 2018-01-11 Bristol-Myers Squibb Company 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
JOP20180040A1 (ar) * 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN109665968B (zh) * 2017-10-16 2022-02-22 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途
WO2020169058A1 (zh) * 2019-02-21 2020-08-27 杭州阿诺生物医药科技有限公司 Pd-l1拮抗剂化合物

Also Published As

Publication number Publication date
IL294209A (en) 2022-08-01
JP2022552693A (ja) 2022-12-19
CN115066423A (zh) 2022-09-16
KR20220121254A (ko) 2022-08-31
EP4083032A1 (en) 2022-11-02
BR112022012737A2 (pt) 2022-09-06
US20230054028A1 (en) 2023-02-23
AU2020413555A1 (en) 2022-06-30
AU2020413555B2 (en) 2024-08-01
CN115066423B (zh) 2024-02-02
EP4083032A4 (en) 2023-10-25
CA3160606A1 (en) 2021-07-01
WO2021129584A1 (zh) 2021-07-01
ZA202206266B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
GEP20207160B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
NZ770222A (en) Bicyclic lactams and methods of use thereof
GEP20207147B (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
EA201991884A3 (ru) Ингибиторы g12c kras
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2018015302A (es) Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
PH12017501095A1 (en) Piperidine derivatives as hdac1/2 inhibitors
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
PH12014502586A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
ZA202206266B (en) Pd-l1 antagonist compound
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
WO2018039077A8 (en) Therapeutic compounds
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
MX2022002443A (es) Compuestos inhibidores de perk.
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.